Meda buys Acton for $135M+, snags asthma inhaler

Swedish pharmaceutical company Meda bought Massachusetts-based Acton Pharmaceuticals, the maker of a new asthma drug-device combo, for more than $135 million plus milestone payments. The inhaler, Aerospan, which delivers the corticosteroid flunisolide, is the only FDA-approved inhaler in its class to incorporate a built-in spacer device, which helps control the delivery of the drug to the lung, according to the company. On top of the agreed-upon upfront payment, Meda offered milestone payments of more than $10 million. Release

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.